Engineered immune cells tackle brain cancer in early trial
NCT ID NCT04134117
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This early-phase study tested a personalized cell therapy called tisagenlecleucel in 13 patients with primary central nervous system lymphoma, a rare brain cancer. The main goal was to check safety, and researchers also looked at whether the treatment shrank tumors. Participants were 60 years or older who had not responded to or could not tolerate standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.